Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed cancer (at diagnosis or relapse), including any of the following:
• * Leukemia and/or lymphoma (closed to accrual)
• * Bone tumor (e.g., Ewing's sarcoma or osteosarcoma) (closed to accrual)
• * Neuroblastoma (closed to accrual)
• * High-grade glial tumor
• * Low-grade glial tumor
• * Ependymoma
• * Medulloblastoma and/or primitive neuroectodermal tumor (PNET)
• * Miscellaneous tumor (closed to accrual)
• * Brain stem glioma, defined as intrinsic tumors of the pons causing diffuse enlargement
• * Brain stem glioma that progressed after radiotherapy does not require histological confirmation
• * Duration of symptoms at the time of diagnosis must be \< 3 months
• * Symptoms should consist of cranial nerve deficits, ataxia, and/or long tract signs
• Relapsed or progressive poor prognosis disease for which no available curative therapy exists
• PATIENT CHARACTERISTICS:
• Karnofsky performance status 50-100% OR Lansky play scale 50-100% (for infants)
• Life expectancy \> 2 months
• Platelet count \> 75,000/mm\^3 (transfusion independent)
• Absolute neutrophil count \> 1,000/mm\^3 (in patients without bone marrow disease)
• Hemoglobin ≥ 9.0 g/dL
• Creatinine \< 1.5 mg/dL OR creatinine clearance or glomerular filtration rate ≥ 70 mL/min
• Bilirubin ≤ 1.5 mg/dL
• SGPT ≤ 3 times normal
• SGOT ≤ 3 times normal (4 times normal for patients on ranitidine hydrochloride)
• Alkaline phosphatase ≤ 3 times normal
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective double-method contraception during and for 2 months after completion of study treatment
• Must be willing to participate in the Celgene STEPS® program
• Recent thromboembolic disease (e.g., deep vein thrombosis or pulmonary embolism) allowed if patient is clinically stable and the thromboembolic event occurred \> 3 weeks prior to study entry
• No active infection
• No active uncontrolled cardiac, hepatic, renal, or psychiatric disease ≥ grade 3
• No known allergies to sulfonamides
• No concurrent illness that would obscure toxicity or dangerously alter drug metabolism
• No other serious medical illness
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Recovered from prior therapy
• Prior chemotherapy and/or radiotherapy allowed
• Prior celecoxib allowed
• Prior standard-dose IV etoposide and cyclophosphamide administered in 3-week courses allowed
• No prior oral therapy with etoposide, thalidomide, cyclophosphamide, or fenofibrate for \> 2 months in duration
• No other concurrent investigational agents
• No other concurrent nonsteroidal anti-inflammatory drugs
• Concurrent steroids and/or antiseizure medications allowed